small integral membrane protein 10 like 2AGenealiases: LED · LINC00086 · LINC0086 · NCRNA00086
Q-omics provides the consensus-scored SMIM10L2A profile across patient tissues and cancer cell-line models. SMIM10L2A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SMIM10L2A is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, SMIM10L2A RNA expression shows 17,191 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, THCA, and THYM as cancer lineages where SMIM10L2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM10L2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM10L2A survival associations across molecular data types. SMIM10L2A RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM10L2A RNA expression–survival associations across cancer types. High SMIM10L2A expression shows unfavorable associations in UCEC, but favorable associations in UVM, KIRC, MESO, KIRP and ACC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SMIM10L2A RNA expression.
This table summarizes SMIM10L2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM10L2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM10L2A shows lower tumor expression in STAD, BRCA, LUSC, HNSC and BLCA and higher tumor expression in THCA. The THCA box plot shows higher SMIM10L2A RNA expression in tumor versus normal tissue (log2 FC = +1.499, t-test p < 0.001).
This table shows molecular features associated with SMIM10L2A in patient tissues and cancer cell lines. In patient samples, SMIM10L2A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SMIM10L2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
